Clinical Trials Logo

Filter by:
NCT ID: NCT04927364 Active, not recruiting - Clinical trials for Transcranial Magnetic Stimulation

Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder

Start date: September 6, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with an alcohol use disorder (AUD).

NCT ID: NCT04926948 Active, not recruiting - Clinical trials for Pleural Mesothelial Neoplasm

Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma

Start date: July 12, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.

NCT ID: NCT04926922 Active, not recruiting - HIV Clinical Trials

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

Start date: July 27, 2021
Phase:
Study type: Observational

Background: Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster. TB is a leading cause of death among people in the West African country of Liberia. Researchers want to find an effective testing method for latent tuberculosis infection (LTBI) to help people living with HIV in Liberia. Objective: To compare the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) as LTBI screening tests in people living with HIV in Liberia. Eligibility: People ages 18 and older who take part in NIH study #19-I-N014 and are scheduled to have or have had IGRA at a Month 12 HONOR study visit. Design: Participants will be screened with a medical history and physical exam. Their medical records and HONOR study records will be reviewed. Participants will have TST. Purified protein derivative will be placed in the skin of their forearm. They will be observed for adverse reactions for 15 minutes. Between 48 and 72 hours after placement, they will have a second study visit to have the TST read. If they miss this time frame, they can return up to 7 days after placement. If they have a positive test result, they will have a chest x-ray. They will have a third study visit to review the results of the chest x-ray. They will be referred for clinical care if needed. They will take a pregnancy test if needed. Participation will last from 2 days to 6 weeks.

NCT ID: NCT04926831 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Geometry-N
Start date: August 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

NCT ID: NCT04926207 Active, not recruiting - Obesity Clinical Trials

The Effects of Interrupting Prolonged Sitting With Bouts of Physical Activity on Neurocognitive Function in Obesity

SITLess
Start date: May 3, 2021
Phase: N/A
Study type: Interventional

It is projected that by 2030 almost 50% of adults in the USA will have obesity. High sedentariness and physical inactivity contribute to the obesity pandemic. Neurocognitive deficits compound the global burden of obesity. Specifically, adults with obesity underperform on tasks of executive functioning, which underpin goal-directed behavior and have been linked to occupational success. Growing evidence suggests poorer executive functioning among more sedentary adults. Emergent studies have shown that accumulating sedentary time in prolonged bouts (e.g., remaining sedentary continuously 20 min or more) may decrease the ability to control distractions along with working memory. Interrupting prolonged sitting with brief bouts of physical activity is an effective strategy to improve postprandial glucose metabolism. However, the effects of this simple intervention on neural processes supporting executive functioning remain unknown. Accordingly, the aim of this study is to test the effects of interrupting prolonged sitting with frequent (every 30 min) but brief (3 min) physical activity bouts on inhibitory control, working memory, and their neuroelectric indices (N2, P3a, and P3b components of event-related brain potentials). Our secondary aim is to explore the potential mechanisms underlying the effects of interrupting prolonged sitting with physical activity on cognitive and brain function through glucose metabolism and insulin physiology. Findings from this study will help advance our understanding of how restructuring sedentary time may help improve cognitive and brain functions among adults with obesity.

NCT ID: NCT04926181 Active, not recruiting - Prostate Cancer Clinical Trials

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) biopsies. This indicates that epigenetic dysregulation leads to reprogramming away from an AR-driven transcriptional program. Therefore, continuation of AR blockade in the form of apalutamide may provide additive benefit compared to immune checkpoint blockade alone. The investigators hypothesize that the combination of apalutamide plus cetrelimab will achieve a clinically significant composite response rate with sufficient durability of response in mCRPC patients with evidence of treatment-emergent small cell neuroendocrine prostate cancer

NCT ID: NCT04925960 Active, not recruiting - Pmm2-CDG Clinical Trials

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Start date: November 10, 2022
Phase: Phase 3
Study type: Interventional

This is a prospective, single-center, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG on oral epalrestat therapy vs. placebo.

NCT ID: NCT04925791 Active, not recruiting - Hip Fractures Clinical Trials

Does Limb Pre-Conditioning Reduce Pain After Hip Arthroscopy

Start date: October 18, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the utilization of Ischemic Pre-Conditioning 24-hours prior to hip arthroscopy decreases patient's post-operative pain and opioid consumption.

NCT ID: NCT04925752 Active, not recruiting - Clinical trials for Pre-Exposure Prophylaxis of HIV Infection

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

PURPOSE 2
Start date: June 28, 2021
Phase: Phase 3
Study type: Interventional

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

NCT ID: NCT04924608 Active, not recruiting - Neurofibromatosis 1 Clinical Trials

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

KOMET
Start date: November 19, 2021
Phase: Phase 3
Study type: Interventional

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.